Antitumour activity of chlorimidazine on transplantable mouse tumour systems.
The antitumour activity of the newly synthesized compound, chlorimidazine (1-chlorethyl-2-chlormethyl-2-imidazoline hydrochloride), has been investigated on mouse tumour systems including L 1210 and P 388 leukaemias and Lewis lung carcinoma. It has been found that optimum treatment schedules resulted in 153% T/C in mice with L 1210 leukaemia, 159% T/C in mice bearing P 388 leukaemia and 68% TWI for Lewis lung carcinoma. Due to the results obtained the compound acts as a novel potential antitumour agent that warrants further evaluation.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007093:Imidazoles / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*
D000970:Antineoplastic Agents; D007093:Imidazoles; C047705:chlorimidazine